← Leaderboards
Joshua Patrick Lewis
University Of Maryland Baltimore
$5,160,188
Attributed
$5,160,188
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $880K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,160,188 · 4
By mechanism
R01$4,120,848 · 2
K23$806,090 · 1
R21$233,250 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Alan R. Shuldiner$66,143,496
- Robert E McCullumsmith$6,183,971
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsPreventGeneticParticipantResponseGenotypeVariantProspectiveGenesRandomizedResistanceAllelesClopidogrelPercutaneous Coronary InterventionEventBlood PlateletsPhysiciansAspirinCardiovascular SystemAcute Coronary SyndromePharmacogenomicsPlatelet AggregationCardiovascular DiseasesDesign
Grant awards (15)
Clinical and Nutrigenetic Assessment of Zinc in Patients with Prediabetes$763,337
R01 · FY2025 · DK · contact PI
Integration of Pharmacogenomics and Metabolomics in the Study of Antiplatelet Efficacy$116,625
R21 · FY2025 · HL · contact PI
Clinical and Nutrigenetic Assessment of Zinc in Patients with Prediabetes$732,803
R01 · FY2024 · DK · contact PI
Integration of Pharmacogenomics and Metabolomics in the Study of Antiplatelet Efficacy$116,625
R21 · FY2024 · HL · contact PI
Clinical and Nutrigenetic Assessment of Zinc in Patients with Prediabetes$770,708
R01 · FY2023 · DK · contact PI
The Impact of Carboxylesterase 1 ( CES1 ) in Personalized Antiplalet Therapy$309,000
R01 · FY2021 · HL · contact PI
The Impact of Carboxylesterase 1 ( CES1 ) in Personalized Antiplalet Therapy$386,250
R01 · FY2020 · HL · contact PI
The Impact of Carboxylesterase 1 ( CES1 ) in Personalized Antiplalet Therapy$386,250
R01 · FY2019 · HL · contact PI
The Impact of Carboxylesterase 1 ( CES1 ) in Personalized Antiplalet Therapy$386,250
R01 · FY2018 · HL · contact PI
The Impact of Carboxylesterase 1 ( CES1 ) in Personalized Antiplalet Therapy$386,250
R01 · FY2017 · HL · contact PI
Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy$161,218
K23 · FY2016 · GM · contact PI
Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy$161,218
K23 · FY2015 · GM · contact PI
Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy$161,218
K23 · FY2014 · GM · contact PI
Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy$161,218
K23 · FY2013 · GM · contact PI
Aspirin Pharmacogenomics: Role of PEAR1 in Personalized Anti-Platelet Therapy$161,218
K23 · FY2012 · GM · contact PI